VDJ-recombination of the B-cell Receptor Following Hematopoietic Stem Cell Transplantation
NCT ID: NCT07346820
Last Updated: 2026-01-16
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NOT_YET_RECRUITING
Total Enrollment
65 participants
Study Classification
OBSERVATIONAL
Study Start Date
2026-02-01
Study Completion Date
2036-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
When a person undergoes a stem cell transplant-an important procedure used to treat serious blood diseases such as leukaemia, lymphoma, or myeloma-the entire immune system is affected. The transplant essentially "resets" the immune system, meaning that the patient loses much of the protection against infections that has been built up over a lifetime. After the transplant, the patient therefore needs to be revaccinated against several diseases, such as tetanus, diphtheria, polio, COVID-19, and pneumococcal disease.
In this study, we aim to investigate how B cells-the immune cells that produce antibodies-reconstitute after a stem cell transplant. We are particularly interested in a genetic process called VDJ recombination, through which each B cell develops a unique receptor that enables it to recognize and fight a specific virus or bacterium. This process is what makes our immune system so effective. But what happens to this diversity after the entire immune system has been restarted with new stem cells? Does the body regain the same ability to recognize pathogens? Are there differences between patients who receive their own stem cells (autologous transplantation) and those who receive stem cells from another person (allogeneic transplantation)?
To answer these questions, we will follow patients undergoing stem cell transplantation at Umeå University Hospital. We will collect blood samples before and after the transplantation and will assess whether-and how well-patients generate antibodies in response to the vaccines given after transplantation. Using flow cytometry and genetic analyses, we will examine both which B-cell populations are generated and what their genetic architecture looks like. The goal is to understand how the new immune system is rebuilt after transplantation and, ultimately, to help improve vaccination strategies and infection prevention for this vulnerable patient group
In this study, we aim to investigate how B cells-the immune cells that produce antibodies-reconstitute after a stem cell transplant. We are particularly interested in a genetic process called VDJ recombination, through which each B cell develops a unique receptor that enables it to recognize and fight a specific virus or bacterium. This process is what makes our immune system so effective. But what happens to this diversity after the entire immune system has been restarted with new stem cells? Does the body regain the same ability to recognize pathogens? Are there differences between patients who receive their own stem cells (autologous transplantation) and those who receive stem cells from another person (allogeneic transplantation)?
To answer these questions, we will follow patients undergoing stem cell transplantation at Umeå University Hospital. We will collect blood samples before and after the transplantation and will assess whether-and how well-patients generate antibodies in response to the vaccines given after transplantation. Using flow cytometry and genetic analyses, we will examine both which B-cell populations are generated and what their genetic architecture looks like. The goal is to understand how the new immune system is rebuilt after transplantation and, ultimately, to help improve vaccination strategies and infection prevention for this vulnerable patient group
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
NCT01206309
Graft vs Host Disease
Cutaneous Sclerosis
Bronchiolitis Obliterans
COMPLETED
Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation
NCT03836690
Lymphoma
Leukemia
Myeloma
+4 more
UNKNOWN
PHASE1
Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
NCT00003538
Cancer
COMPLETED
NA
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies
NCT00079391
Hematologic Malignancies
Bone Marrow Transplant Rejection
COMPLETED
PHASE2
Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hematopoietic Cell Transplantation
NCT07235501
Graft Versus Host Disease
Hematopoietic and Lymphatic System Neoplasm
Malignant Solid Neoplasm
NOT_YET_RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Purpose and aims
The humoral immune system is critical for mounting protective responses against severe microbial infections. This is a highly specific response, where naïve B cell clones that recognize epitopes on a pathogen are activated, clonally expands and differentiates to memory B cells and antibody producing plasma cells.
The specificity of the response is dependent on VDJ recombination that creates naïve B cell clones, each with a distinct B cell receptor that carry unique variable (V), diversity (D) and joining segments. While the process of VDJ recombination is well investigated, it is not well established how/if VDJ recombination is affected in B cells after autologous or allogeneic stem cell transplantation. Such knowledge may improve on strategies to re-vaccinate vulnerable patient groups that require stem cell transplantation to alleviate a number of haematological disorders. Here, we will utilize samples from individuals before and after haematological stem cell transplantation to better define the impact on VDJ recombination and clonal responses to vaccine antigens.
Background
Stem cell transplantation is a procedure where most/all hematopoietic cells are eradicated from a patient and replaced by new stem cells that are derived from "self" (autologous) or from an MHC matched donor. Upon a successful stem cell transfer, new and healthy hematopoietic cells will emerge. After the procedure immunity to several vaccine preventable diseases are lost or severely impaired putting the patient at risk.
Following transplantation patients are vaccinated against several infectious diseases according to an established vaccine schedule. This provides an opportunity to study VDJ recombination in a situation where the immune system is "reset" - compare and contrast the situation to before the procedure as well as differences between autologous and allogenic transplantation.
A standardized vaccination schedule based on recommendations by the European Conference on Infections in Leukemia (ECIL) is implemented to HSCT patients. Vaccinations against pneumococcal infections, capsulated haemophilus influenzae, tetanus, diphtheria, polio, pertussis, covid19 and influenzae are recommended to all. Further vaccination may be considered according to the preferences of the patient.
B cells are critical for humoral immune responses, as they specifically respond to an antigen and then differentiate into antibody producing plasma cells, and to memory B cells. The importance of this for protection against a primary infection is readily illuminated by susceptibility to severe infectious disease if the humoral immune system is defect or after treatment with B cell depleting drugs, such as anti-CD20 antibodies. In addition, the generation of immunological memory then protects us against re-infection with the same pathogen. Of critical importance for this response is the antigen-specificity of the B-cell receptor (BCR) of naïve B cell clones.
The BCR comprise an immunoglobin heavy and light chain with a distinct specificity. The specificity is created by VDJ recombination where one of numerous V, D and J segments are combined into a VDJ region of the heavy chain, and one of numerous V and J segments are combined into a light chain. The combination of these ensures that emerging naïve B cell clones each has a distinct and unique capacity to recognize an epitope. The diversity that is generated ensures that the immune system can respond clonally to almost any foreign pathogen it encounters. By BCR sequencing of B cells, it is therefore possible to determine exactly which V, D or J segments has randomly been recombined to recognize a specific antigen. T cells undergo a similar process of VDJ recombination after maturation in the thymus.
After stem cell transplantation, the VJ-segment of the beta chain T cell receptor develop with a relative symmetry but reduced complexity, as compared with the donor. This may explain why B cells may demonstrate reduced T cell-dependent somatic hypermutation after transplantation. However, it is not well understood if a similar set of B cell clones will emerge after autologous stem cell transplantation or that of an allogenic donor. Since stem cell transplant patients undergo vaccination, this will allow us to closely study the process of antigen-specific VDJ recombination pre- and post "reset" of the immune system, and to couple this to antigenspecific responses after vaccination. We hypothesize that this will reveal further information of how/if the nature of the transplant will affect downstream VDJ recombination and lead to an altered capacity or pattern of immune recognition.
Moreover, it has been shown that impaired humoral immune responses during ageing may be dependent on extrinsic rather that intrinsic factors that affect Bcl6 and CD39-expression the T cell compartment. The potential availability of samples from allogenic donors with age variation will allow for potential verification of these results in humans.
Project description
Study structure
This is an observational cohort study following patients after stem cell transplantation examining the B-cell development following the standardized and established vaccine schedule given as part of clinical practice. In the current version of this schedule in Västerbotten vaccinations against pneumococci, haemophilus influenzae, COVID-19, tetanus, diphtheria, polio and whopping cough are included. Measles, mumps and rubella vaccination may be given following negative immunity test at 24 months from transplantation.
Sampling
i. Sampling before immunosuppressive medication is initiated
ii. Sampling when admitted for stem cell transplantation
iii. Sampling prior to each vaccination time point up until 24 months from transplantation.
iv. In allogenic transplantation sampling of related donor if available (sampling once).
Blood sample analysis
B cell characterization and VDJ sequencing
Antigen specific identification of B cells; We will use established methodology to detect antigen specific B cells. In brief, biotin- and fluorochrome labelled SARS-CoV-2 protein or Influenza type A hemagglutinin protein will be utilized to determine vaccine specific CD19+ CD20+ B cells by flow cytometry. We will focus on cells that has undergone thymus-dependent B cell responses (CD27+IgD-) and phenotype these for activation markers such as DAF and CD71.
For examination of the VDJ repertoire preand post transplantation, we will mainly rely on bulk sequencing but may subject samples to single cell sequencing to reveal if heavy and light chain pairing is affected by the transplantation. We also aim to dissect transcriptional patterns in B cells to reveal specific patterns or molecules that actively predict efficient establishment of Bmem or plasmablasts after stem cell transplantation. For transcriptional patterns, we will perform 10x Chromium single cell gene expression to provide the single cell transcriptome from up to 10,000 vaccine-specific Bmem cells. By combinatorial analysis of both phenotypic and transcriptomic data, we will be able to identify biomarkers or gene expression patterns that predict robust establishment of "boostable" immune memory after stem cell transplantation.
The humoral immune system is critical for mounting protective responses against severe microbial infections. This is a highly specific response, where naïve B cell clones that recognize epitopes on a pathogen are activated, clonally expands and differentiates to memory B cells and antibody producing plasma cells.
The specificity of the response is dependent on VDJ recombination that creates naïve B cell clones, each with a distinct B cell receptor that carry unique variable (V), diversity (D) and joining segments. While the process of VDJ recombination is well investigated, it is not well established how/if VDJ recombination is affected in B cells after autologous or allogeneic stem cell transplantation. Such knowledge may improve on strategies to re-vaccinate vulnerable patient groups that require stem cell transplantation to alleviate a number of haematological disorders. Here, we will utilize samples from individuals before and after haematological stem cell transplantation to better define the impact on VDJ recombination and clonal responses to vaccine antigens.
Background
Stem cell transplantation is a procedure where most/all hematopoietic cells are eradicated from a patient and replaced by new stem cells that are derived from "self" (autologous) or from an MHC matched donor. Upon a successful stem cell transfer, new and healthy hematopoietic cells will emerge. After the procedure immunity to several vaccine preventable diseases are lost or severely impaired putting the patient at risk.
Following transplantation patients are vaccinated against several infectious diseases according to an established vaccine schedule. This provides an opportunity to study VDJ recombination in a situation where the immune system is "reset" - compare and contrast the situation to before the procedure as well as differences between autologous and allogenic transplantation.
A standardized vaccination schedule based on recommendations by the European Conference on Infections in Leukemia (ECIL) is implemented to HSCT patients. Vaccinations against pneumococcal infections, capsulated haemophilus influenzae, tetanus, diphtheria, polio, pertussis, covid19 and influenzae are recommended to all. Further vaccination may be considered according to the preferences of the patient.
B cells are critical for humoral immune responses, as they specifically respond to an antigen and then differentiate into antibody producing plasma cells, and to memory B cells. The importance of this for protection against a primary infection is readily illuminated by susceptibility to severe infectious disease if the humoral immune system is defect or after treatment with B cell depleting drugs, such as anti-CD20 antibodies. In addition, the generation of immunological memory then protects us against re-infection with the same pathogen. Of critical importance for this response is the antigen-specificity of the B-cell receptor (BCR) of naïve B cell clones.
The BCR comprise an immunoglobin heavy and light chain with a distinct specificity. The specificity is created by VDJ recombination where one of numerous V, D and J segments are combined into a VDJ region of the heavy chain, and one of numerous V and J segments are combined into a light chain. The combination of these ensures that emerging naïve B cell clones each has a distinct and unique capacity to recognize an epitope. The diversity that is generated ensures that the immune system can respond clonally to almost any foreign pathogen it encounters. By BCR sequencing of B cells, it is therefore possible to determine exactly which V, D or J segments has randomly been recombined to recognize a specific antigen. T cells undergo a similar process of VDJ recombination after maturation in the thymus.
After stem cell transplantation, the VJ-segment of the beta chain T cell receptor develop with a relative symmetry but reduced complexity, as compared with the donor. This may explain why B cells may demonstrate reduced T cell-dependent somatic hypermutation after transplantation. However, it is not well understood if a similar set of B cell clones will emerge after autologous stem cell transplantation or that of an allogenic donor. Since stem cell transplant patients undergo vaccination, this will allow us to closely study the process of antigen-specific VDJ recombination pre- and post "reset" of the immune system, and to couple this to antigenspecific responses after vaccination. We hypothesize that this will reveal further information of how/if the nature of the transplant will affect downstream VDJ recombination and lead to an altered capacity or pattern of immune recognition.
Moreover, it has been shown that impaired humoral immune responses during ageing may be dependent on extrinsic rather that intrinsic factors that affect Bcl6 and CD39-expression the T cell compartment. The potential availability of samples from allogenic donors with age variation will allow for potential verification of these results in humans.
Project description
Study structure
This is an observational cohort study following patients after stem cell transplantation examining the B-cell development following the standardized and established vaccine schedule given as part of clinical practice. In the current version of this schedule in Västerbotten vaccinations against pneumococci, haemophilus influenzae, COVID-19, tetanus, diphtheria, polio and whopping cough are included. Measles, mumps and rubella vaccination may be given following negative immunity test at 24 months from transplantation.
Sampling
i. Sampling before immunosuppressive medication is initiated
ii. Sampling when admitted for stem cell transplantation
iii. Sampling prior to each vaccination time point up until 24 months from transplantation.
iv. In allogenic transplantation sampling of related donor if available (sampling once).
Blood sample analysis
B cell characterization and VDJ sequencing
Antigen specific identification of B cells; We will use established methodology to detect antigen specific B cells. In brief, biotin- and fluorochrome labelled SARS-CoV-2 protein or Influenza type A hemagglutinin protein will be utilized to determine vaccine specific CD19+ CD20+ B cells by flow cytometry. We will focus on cells that has undergone thymus-dependent B cell responses (CD27+IgD-) and phenotype these for activation markers such as DAF and CD71.
For examination of the VDJ repertoire preand post transplantation, we will mainly rely on bulk sequencing but may subject samples to single cell sequencing to reveal if heavy and light chain pairing is affected by the transplantation. We also aim to dissect transcriptional patterns in B cells to reveal specific patterns or molecules that actively predict efficient establishment of Bmem or plasmablasts after stem cell transplantation. For transcriptional patterns, we will perform 10x Chromium single cell gene expression to provide the single cell transcriptome from up to 10,000 vaccine-specific Bmem cells. By combinatorial analysis of both phenotypic and transcriptomic data, we will be able to identify biomarkers or gene expression patterns that predict robust establishment of "boostable" immune memory after stem cell transplantation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Stem Cell Transplantation, Hematopoietic
V(D)J Recombination
Receptors, Antigen, B-Cel
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients undergoing autologous stem cell transplantation
No interventions assigned to this group
Patients undergoing allogenic stem cell transplantation
No interventions assigned to this group
Stem cell donors
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \> 18 years.
* Willing and able to participate in all parts of the study.
* Signed written consent.
* Patients with a plasma cell disease of lymphoma that qualify for autologous hematological stem cell transplantation determined by the attending physician OR Patients with a condition for which allogenic stem cell transplantation could be needed and qualify for haematological stem cell transplantation according to the attending physician OR Stem cell donor, donating to a study participant.
* Willing and able to participate in all parts of the study.
* Signed written consent.
* Patients with a plasma cell disease of lymphoma that qualify for autologous hematological stem cell transplantation determined by the attending physician OR Patients with a condition for which allogenic stem cell transplantation could be needed and qualify for haematological stem cell transplantation according to the attending physician OR Stem cell donor, donating to a study participant.
Exclusion Criteria
* Unable to give informed consent.
* Not suitable for participation in the study according to the view of the attending physician.
* Previous participation in this trial.
* Not suitable for participation in the study according to the view of the attending physician.
* Previous participation in this trial.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Region Västerbotten
OTHER_GOV
Sponsor Role
collaborator
Umeå University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Umeå university hospital
Umeå, , Sweden
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Sweden
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005 Oct 15;106(8):2912-9. doi: 10.1182/blood-2005-05-2004. Epub 2005 Jun 30.
Reference Type
BACKGROUND
Dernstedt A, Leidig J, Holm A, Kerkman PF, Mjosberg J, Ahlm C, Henriksson J, Hultdin M, Forsell MNE. Regulation of Decay Accelerating Factor Primes Human Germinal Center B Cells for Phagocytosis. Front Immunol. 2021 Jan 5;11:599647. doi: 10.3389/fimmu.2020.599647. eCollection 2020.
Reference Type
BACKGROUND
Kaku CI, Champney ER, Normark J, Garcia M, Johnson CE, Ahlm C, Christ W, Sakharkar M, Ackerman ME, Klingstrom J, Forsell MNE, Walker LM. Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination. Science. 2022 Mar 4;375(6584):1041-1047. doi: 10.1126/science.abn2688. Epub 2022 Feb 10.
Reference Type
BACKGROUND
Fisher JS, Adan-Barrientos I, Kumar NR, Lancaster JN. The aged microenvironment impairs BCL6 and CD40L induction in CD4+ T follicular helper cell differentiation. Aging Cell. 2024 Jun;23(6):e14140. doi: 10.1111/acel.14140. Epub 2024 Mar 13.
Reference Type
BACKGROUND
Suzuki I, Milner EC, Glas AM, Hufnagle WO, Rao SP, Pfister L, Nottenburg C. Immunoglobulin heavy chain variable region gene usage in bone marrow transplant recipients: lack of somatic mutation indicates a maturational arrest. Blood. 1996 Mar 1;87(5):1873-80.
Reference Type
BACKGROUND
Meier JA, Haque M, Fawaz M, Abdeen H, Coffey D, Towlerton A, Abdeen A, Toor A, Warren E, Reed J, Kanakry CG, Keating A, Luznik L, Toor AA. T Cell Repertoire Evolution after Allogeneic Bone Marrow Transplantation: An Organizational Perspective. Biol Blood Marrow Transplant. 2019 May;25(5):868-882. doi: 10.1016/j.bbmt.2019.01.021. Epub 2019 Jan 21.
Reference Type
BACKGROUND
Cesaro S, Mikulska M, Hirsch HH, Styczynski J, Meylan S, Cordonnier C, Navarro D, von Lilienfeld-Toal M, Mehra V, Marchesi F, Besson C, Masculano RC, Beutel G, Einsele H, Maertens J, de la Camara R; ECIL 9; Ljungman P, Pagano L. Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9). Leukemia. 2023 Sep;37(9):1933-1938. doi: 10.1038/s41375-023-01938-5. Epub 2023 Jul 17. No abstract available.
Reference Type
BACKGROUND
Cordonnier C, Einarsdottir S, Cesaro S, Di Blasi R, Mikulska M, Rieger C, de Lavallade H, Gallo G, Lehrnbecher T, Engelhard D, Ljungman P; European Conference on Infections in Leukaemia group. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019 Jun;19(6):e200-e212. doi: 10.1016/S1473-3099(18)30600-5. Epub 2019 Feb 8.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
https://rvlitablobprod.blob.core.windows.net/rvlitablobprod/73697.pdf
Vaccination schedule after stem cell transplantation used in Umeå
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
The VReST study
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood
NCT00143884
TERMINATED
PHASE2
B-Cell Reconstitution After Hematopoietic Stem Cell Transplantation
NCT04682314
UNKNOWN
Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant
NCT00898612
WITHDRAWN
T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation
NCT00306332
TERMINATED
PHASE3
Immuno 1: Immune Reconstitution Following Conventional or High-Dose Chemotherapy With Stem Cell Transplant
NCT00231712
UNKNOWN
Complement and Graft-versus-host Disease
NCT01520623
COMPLETED
NA
Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT
NCT03939585
WITHDRAWN
PHASE1
Immune Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation
NCT03233659
COMPLETED
Study Through Imaging of Visceral Lymphoid Organs in Patients With SCID Who Have Recieved Bone Marrow Allograft
NCT04246840
COMPLETED
Reduced Intensity Haploidentical Transplant for Hematological Malignancies
NCT01162096
COMPLETED
PHASE1/PHASE2
Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease
NCT00001872
COMPLETED
Prospective Phase II Study for Assessment of Regulatory Immune Cell Populations After Allogeneic HSCT
NCT00587574
UNKNOWN
Toward Immune Biomarkers for Tolerance and GvHD in Humans
NCT02319226
UNKNOWN
Pulmonary Complications of Hematopoietic Stem Cell Transplantation
NCT00837681
COMPLETED
Improving Blood Stem Cell Collection and Transplant Procedures
NCT01517035
COMPLETED
PHASE1/PHASE2
Retrospective Study of Viral Reactivation Across All Bone Marrow Transplant Protocols Since 2010
NCT03111745
COMPLETED
Stem Cell Transplantation for Patients With Cancers of the Blood
NCT00467961
COMPLETED
PHASE2
Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell Transplantation
NCT03423706
UNKNOWN
NA
Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia
NCT00001623
COMPLETED
NA
Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR
NCT01611298
COMPLETED
NA
Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients
NCT01991067
COMPLETED
PHASE2
Resiliency in Older Adults Undergoing Bone Marrow Transplant
NCT04188678
COMPLETED
Long-Term Follow-up of People Undergoing Hematopoietic Stem Cell Transplantation
NCT03000244
RECRUITING